Clinical Trial Update: Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating first-line single-agent panitumumab in frail elderly patients with advanced wild-type K-RAS colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED